

MARKED UP CLAIMS

## CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof:





(I)

wherein

$R^1$ is phenyl or 6-membered heteroaryl, optionally substituted with one or more substituents selected from halogen, cyano, $C_{1-4}$-alkyl, halo-$C_{1-4}$-alkyl, $C_{1-4}$alkoxy-$C_{1-4}$alkyl, hydroxy-$C_{1-4}$-alkyl, cyano-$C_{1-4}$-alkyl, amino-$C_{1-4}$-alkyl, $C_{1-4}$-alkylamino-$C_{1-4}$-alkyl, di($C_{1-4}$-alkyl)amino-$C_{1-4}$-alkyl, $-NR^{4A}R^{4B}$, $-NR^6C(O)OR^5$, $-NR^6C(O)R^5$, $-NR^6C(O)NR^{4A}R^{4B}$, $-C(O)NR^{4A}R^{4B}$, $-C(O)R^5$, $-C(O)OR^5$, and $-NR^6S(O)_2R^5$;

~~A is a bond;~~

$R^2$ is $-B-Q-[R^3]_n$ or $-B-R^3$;

wherein n = 1, 2, 3, or 4

B is a bond, O, ~~$NR^4$~~, ~~$-C(O)-$~~ or $C_{1-3}$-alkylene;

Q is saturated or partially unsaturated monocyclic 3-7 membered heterocyclic or $C_{3-7}$-cycloalkyl ring;

when $R^2$ is $-B-Q-[R^3]_n$, $R^3$ is selected from hydrogen, halogen, cyano, amino, hydroxyl, oxo, $C_{1-4}$-alkyl, halo-$C_{1-4}$-alkyl, $C_{1-4}$-alkoxy, $C_{1-4}$alkoxy-$C_{1-4}$alkyl, hydroxy-$C_{1-4}$-alkyl, cyano-$C_{1-4}$-alkyl, amino-$C_{1-4}$-alkyl, $C_{1-4}$-alkylamino-$C_{1-4}$-alkyl, di($C_{1-4}$-alkyl)amino-$C_{1-4}$-alkyl, $-NR^{4A}R^{4B}$, $-NR^6C(O)OR^5$, $-NR^6C(O)R^5$, $-NR^6C(O)NR^{4A}R^{4B}$, $-C(O)NR^{4A}R^{4B}$, $-C(O)R^5$, $-C(O)OR^5$, $-NR^6S(O)_2R^5$, $-S(O)_2R^5$, phenyl-$C_{1-4}$-alkyl and heteroaryl-$C_{1-4}$-alkyl, and wherein any phenyl or heteroaryl residue is optionally substituted with one or more substituents selected from halogen, cyano, $C_{1-4}$-alkyl, halo-$C_{1-4}$-alkyl, $C_{1-4}$-alkoxy, $C_{1-4}$alkoxy-$C_{1-4}$alkyl, hydroxy-$C_{1-4}$-

MARKED UP CLAIMS

alkyl, cyano-$C_{1-4}$-alkyl, amino-$C_{1-4}$-alkyl, $C_{1-4}$-alkylamino-$C_{1-4}$-alkyl, di($C_{1-4}$-alkyl)amino-$C_{1-4}$-alkyl, -$NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{4A}R^{4B}$, -$C(O)NR^{4A}R^{4B}$, -$C(O)R^5$, -$C(O)OR^5$, and -$NR^6S(O)_2R^5$;

when $R^2$ is -B-$R^3$, $R^3$ is selected from amino, $C_{1-4}$-alkoxy, $C_{1-4}$alkoxy-$C_{1-4}$alkyl, hydroxy-$C_{1-4}$-alkyl, cyano-$C_{1-4}$-alkyl, amino-$C_{1-4}$-alkyl, $C_{1-4}$-alkylamino-$C_{1-4}$-alkyl, di($C_{1-4}$-alkyl)amino-$C_{1-4}$-alkyl, -$NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, ~~-$NR^6C(O)R^5$~~, -$NR^6C(O)NR^{4A}R^{4B}$, ~~-$C(O)NR^{4A1}R^{4B}$~~, -$C(O)R^5$, -$NR^6S(O)2R^5$, phenyl-$C_{1-4}$-alkyl and heteroaryl-$C_{1-4}$-alkyl, and wherein any phenyl or heteroaryl residue is optionally substituted with one or more substituents selected from halogen, cyano, $C_{1-4}$-alkyl, halo-$C_{1-4}$-alkyl, $C_{1-4}$-alkoxy, $C_{1-4}$alkoxy-$C_{1-4}$alkyl, hydroxy-$C_{1-4}$-alkyl, cyano-$C_{1-4}$-alkyl, amino-$C_{1-4}$-alkyl, $C_{1-4}$-alkylamino-$C_{1-4}$-alkyl, di($C_{1-4}$-alkyl)amino-$C_{1-4}$-alkyl, -$NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{4A}R^{4B}$, -$C(O)NR^{4A}R^{4B}$, -$C(O)R^5$, -$C(O)OR^5$, and -$NR^6S(O)_2R^5$, provided that when $R^2$ is -B-$R^3$, and B is a bond and $R^3$ is -$C(O)R^5$, then $R^5$ is not hydrogen;


$R^{4A}$, $R^{4B}$ and $R^5$ are each independently selected from hydrogen, $C_{1-4}$-alkyl, hydroxy-$C_{1-4}$-alkyl, halo-$C_{1-4}$-alkyl, cyano-$C_{1-4}$-alkyl, amino-$C_{1-4}$-alkyl, $C_{1-4}$-alkylamino-$C_{1-4}$-alkyl, di($C_{1-4}$-alkyl)-amino-$C_{1-4}$-alkyl ~~or~~ and $C_{1-4}$alkoxy-$C_{1-4}$alkyl; or $R^{4A}$ and $R^{4B}$ together with the nitrogen to which they are attached form a cyclic amino group ~~such as a piperidinyl, piperazinyl, N-substituted piperazinyl, morpholinyl or homopiperidinyl group;~~

~~$R^{4A1}$ is selected from $C_{1-4}$-alkyl, hydroxy-$C_{1-4}$-alkyl, halo-$C_{1-4}$-alkyl, cyano-$C_{1-4}$-alkyl, amino-$C_{1-4}$-alkyl, $C_{1-4}$-alkylamino-$C_{1-4}$-alkyl, di($C_{1-4}$-alkyl)amino-$C_{1-4}$-alkyl or $C_{1-4}$alkoxy-$C_{1-4}$alkyl; or $R^{4A1}$ and $R^{4B}$ together with the nitrogen to which they are attached form a cyclic amino group such as a piperidinyl, piperazinyl, N-substituted piperazinyl, morpholinyl or homopiperidinyl group~~;

$R^6$ is hydrogen or $C_{1-4}$-alkyl; and

~~X is selected from the radicals of formulae (1-16) wherein the bond marked * is attached to $R^1$A and the bond marked ** is attached to $R^2$:~~

MARKED UP CLAIMS




~~wherein~~ Y is selected from hydrogen, hydroxyl, amino, -$NHR^6$, -$OCH_3$;

Z is selected from hydrogen, fluorine, hydroxyl, $C_{1-4}$-alkoxy, halo-$C_{1-4}$-alkyl, $CONH_2$, cyano, $SO_2NH_2$, amino, and -$NHR^6$; and

W is selected from H, $C_{1-4}$-alkyl, halo-$C_{1-4}$-alkyl~~;~~.

~~2. A compound as claimed in claim 1 in which:~~

~~X has the formula 1 and wherein $R^1$, $R^2$, Y, Z and W are as defined in claim 1; or~~

~~X has the formula 2 and wherein $R^1$, $R^2$, Y, Z and W are as defined in claim 1; or~~

~~X has the formula 3 and wherein $R^1$, $R^2$, Y, and Z are as defined in claim 1; or~~

~~X has the formula 4 and wherein $R^1$, $R^2$, Y, and W are as defined in claim 1; or~~

~~X has the formula 5 and wherein $R^1$, $R^2$, and Y are as defined in claim 1; or~~

~~X has the formula 6 and wherein $R^1$, $R^2$, Y, and Z are as defined in claim 1.~~

~~3~~2. A compound as claimed in ~~any preceding~~ claim 1 wherein B is a bond~~, C(O),~~ or methylene~~ or a bond; and/or W is hydrogen; and/or Y is H, OH, or $NH_2$~~.

MARKED UP CLAIMS

43. A compound as claimed in ~~any preceding~~ claim 1 or 2 wherein $R^1$ is ~~:~~

~~(i) an~~ optionally substituted with one or more substituents selected from halogen, cyano, hydroxyl, $C_{1-4}$-alkyl, halo-$C_{1-4}$-alkyl, $C_{1-4}$alkoxy-$C_{1-4}$alkyl, hydroxy-$C_{1-4}$-alkyl, cyano-$C_{1-4}$-alkyl, amino-$C_{1-4}$-alkyl, $C_{1-4}$-alkylamino-$C_{1-4}$-alkyl, di($C_{1-4}$-alkyl)amino-$C_{1-4}$-alkyl, and -$NR^{4A}R^{4B}$~~;~~.

~~or~~

4. ~~(ii)~~ A compound according to claim 1 or 2 wherein $R^1$ is heteroaryl optionally substituted with one or more substituents selected from fluoro, chloro, and $C_{1-4}$-alkyl.

5. A compound as claimed in any of claims 1 to ~~4~~ 3 wherein $R^1$ is phenyl, optionally substituted at the para, meta and ortho positions by one or more substituents selected from hydrogen, fluoro, chloro, cyano, hydroxyl, $C_{1-4}$-alkyl, fluoromethyl, difluoromethyl, ~~or~~ and trifluoromethyl.

6. A compound as claimed in any one of claims 1 to 5 wherein $R^2$ is -B-Q-$[R^3]_n$, and Q is a 7-membered saturated or partially unsaturated 7-membered heterocyclic or cycloalkyl ring including a homomorpholine ring, or a bridged homomorpholine ring wherein the bridge is formed by an ethylene or propylene radical.

~~7. A compound as claimed in any of claims 1 to 5 wherein $R^2$ is -B-Q-$[R^3]_n$, and Q is a 5- or 6-membered saturated or partially unsaturated 5 or 6 membered heterocyclic or cycloalkyl ring.~~

~~8~~7. A compound as claimed in claim ~~7~~ 1 wherein Q is selected from tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, cyclohexyl, ~~or~~ and any of the foregoing rings comprising a bridge formed by an ethylene or propylene radical

~~9~~8. A compound as claimed in any of claims 1 to 5 wherein $R^2$ is morpholin-4-yl, morpholin-4-yl-methyl, oxolan-3-yl, oxolan-3-yl-methyl, oxan-4-ylmethyl, oxan-4-yl, or tetrahydropyridinyl; or wherein $R^2$ is piperidin-4-yl, piperazin-1-yl, piperidin-4-yl-methyl, oxopiperazine, or piperazin-1-yl methyl, any of which being optionally substituted by $R^3$ on the ring, or on the ring nitrogen in the 1-position.

~~10~~9. A compound as claimed in any of claims 1 to 5 wherein $R^2$ is:

MARKED UP CLAIMS

(i) piperidin-1-yl or pyrrolidin-1-yl; or

(ii) morpholine; or

(iii) cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

10. A compound as claimed in claim 1 wherein the cyclic amino group formed by $R^{4A}$ and $R^{4B}$ together with the nitrogen to which they are attached is a ring selected from piperidinyl, piperazinyl, morpholinyl and homopiperidinyl.

11. A compound according to claim 1 wherein $R^2$ is:

(i) ~~an~~ mono- or disubstituted amino group, the substituents being selected from $C_{1-4}$-alkyl, hydroxy-$C_{1-4}$-alkyl, halo-$C_{1-4}$-alkyl, cyano-$C_{1-4}$-alkyl, amino-$C_{1-4}$-alkyl, $C_{1-4}$-alkylamino-$C_{1-4}$-alkyl, hydroxy-$C_{1-4}$-alkylamino-$C_{1-4}$-alkyl, di($C_{1-4}$-alkyl)amino-$C_{1-4}$-alkyl ~~or~~ and $C_{1-4}$alkoxy-$C_{1-4}$alkyl; or

(ii) a group selected from ~~an~~ $C_{1-4}$alkoxy-$C_{1-4}$alkyl, hydroxy-$C_{1-4}$-alkyl, cyano-$C_{1-4}$-alkyl, amino-$C_{1-4}$-alkyl, $C_{1-4}$-alkylamino-$C_{1-4}$-alkyl ~~or~~ and di($C_{1-4}$-alkyl)amino-$C_{1-4}$-alkyl ~~group~~.

12. A compound as claimed in claim 1 which is:

~~4-[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]cyclohexan-1-amine~~

~~1-{4-[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridine-3-yl]piperidin-1-yl}-2-hydroxyethan-1-one~~

~~2-Amino-1-{4-[1-(4-chlorophenyl)-1*H*-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-one~~

~~3-Amino-1-{4-[1-(4-chlorophenyl)-1*H*-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}propan-1-one~~

~~4-[3-(4-Methylphenyl)imidazo[1,5-a]pyrazin-1-yl]morpholine~~

~~4-[3-(4-Chlorophenyl)imidazo[1,5-a]pyrazin-1-yl]morpholine~~

~~3-(4-Chlorophenyl)-1-(oxan-4-yl)imidazo[1,5-a]pyrazine~~

~~1-(4-Chloro-2-fluorophenyl)-3-(oxan-4-yl)-1H-pyrazolo[3,4-c]pyridine~~

~~1-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]pyrrolidin-3-ol~~

~~3-Methoxy-1-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]pyrrolidine~~

~~1-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-ol~~

~~1-[1-(4-Methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxamide~~

~~4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine~~

~~2,2,2-Trifluoroacetic acid; 4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine~~

~~4-[1-(2-Fluoro-4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine~~

~~4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]-2-methylmorpholine~~

~~4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]-3-methylmorpholine~~

MARKED UP CLAIMS

~~3-[1-(4-Methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]-8-oxa-3-azabicyclo[3.2.1]octane~~

~~2,2-Dimethyl-4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine~~

~~Methyl 4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl] morpholine-3-carboxylate~~

~~4-[1-(4-Methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]-1,4-oxazepane~~

~~4-[1-(4-Methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperazin-2-one~~

~~1-[1-(4-Methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-ol~~

~~1-(4-Chlorophenyl)-3-(oxan-4-yl)-1H-pyrrolo[2,3-c]pyridine~~

~~1-(4-Methylphenyl)-3-(oxan-4-yl)-1H-pyrrolo[2,3-c]pyridine~~

~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]morpholine~~

~~4-amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}butan-1-one~~

~~2-Aminoethyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate~~

~~3-(3,6-Dihydro-2H-pyran-4-yl)-2-methyl-1-(4-methylphenyl)-1H-pyrrolo[2,3-c]pyridine~~

4-[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl] -1,2,3,6-tetrahydropyridine;

1-(4-Chlorophenyl)-3-piperidin-4-yl-1*H*-pyrrolo[2,3-*c*]pyridine;

*tert*-Butyl *N*-{4-[1-(4-chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]cyclohexyl}carbamate;

4-[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]cyclohexan-1-amine;

4-[1-(4-Chloro-2-methylphenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]cyclohexan-1-amine;

1-{4-[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]piperidin-1-yl}-2-(dimethylamino)ethan-1-one;

1-{4-[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridine-3-yl]piperidin-1-yl}-2-hydroxyethan-1-one;

2-Amino-1-{4-[1-(4-chlorophenyl)-1*H*-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-one;

3-Amino-1-{4-[1-(4-chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]piperidin-1-yl}propan-1-one;

2-{4-[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]piperidin-1-yl}ethan-1-ol;

4-[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]-1-(1*H*-pyrazol-3-ylmethyl)piperidine;

4-[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]-1-[(1-methyl-1*H*-pyrazol-4-yl)-methyl]piperidine;

3-{4-[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-c]pyridine-3-yl]piperidin-1-yl}propanenitrile;

4-{4-[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]piperidin-1-yl}butanenitrile;

[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]methanol;

1-{[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]methyl}-4-methylpiperazine;

*tert*-Butyl 4-{[1-(4-chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl] methyl}piperazine-1-carboxylate;

MARKED UP CLAIMS

1-{[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]methyl}piperazine;
2-(1-{[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]methyl}piperidin-4-yl)ethan-1-ol;
(1-{[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]methyl}piperidin-4-yl)methanol;
4-{[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]methyl}morpholine;
1-{[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]methyl}piperidin-4-ol;
2-({[1-(4-Chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]methyl}amino)ethan-1-ol;
1-(4-Chlorophenyl)-3-(oxan-4-yl)-1H-pyrrolo[2,3-c]pyridine;
1-(4-Methylphenyl)-3-(oxan-4-yl)-1H-pyrrolo[2,3-c]pyridine;
5-Chloro-2-[3-(oxan-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl]pyridine;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]morpholine;
4-amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}butan-1-one;
2-Aminoethyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate;
or
3-(3,6-Dihydro-2H-pyran-4-yl)-2-methyl-1-(4-methylphenyl)-1H-pyrrolo[2,3-c]pyridine
~~or~~ and a pharmaceutically acceptable salts, or N-oxides thereof.

13. A pharmaceutical composition comprising a compound as claimed in any of ~~the preceding~~ claims 1 to 12, together with one or more pharmaceutically acceptable carriers and/or excipients

14. A compound as claimed in any of claims 1 to 12 for use in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.

15. A compound as claimed in claim 14, wherein the inflammation or inflammatory disease or immune or autoimmune disorder is arthritis ~~(~~including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis and psoriatic arthritis~~)~~, synovitis, vasculitis, a condition associated with inflammation of the bowel ~~(~~including Crohn's disease, ulcerative colitis, inflammatory bowel disease and irritable bowel syndrome~~)~~, atherosclerosis, multiple sclerosis, Alzheimer's disease, vascular dementia, a pulmonary inflammatory disease ~~(~~including asthma, chronic obstructive pulmonary disease and acute respiratory distress syndrome~~)~~, a fibrotic disease ~~(~~including idiopathic pulmonary fibrosis, cardiac fibrosis and systemic sclerosis ~~(~~scleroderma~~))~~, an inflammatory disease of the skin ~~(~~including contact dermatitis, atopic dermatitis and psoriasis), systemic inflammatory response syndrome, sepsis, an inflammatory and/or autoimmune condition of the liver ~~(~~including autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, sclerosing cholangitis, and autoimmune cholangitis~~)~~, diabetes

MARKED UP CLAIMS

(type I or II) and/or the complications thereof, chronic heart failure, congestive heart failure, an ischemic disease (including stroke and ischemia-reperfusion injury) or myocardial infarction and/or the complications thereof.